Stay updated on ABP 798 vs. Rituximab in RA Clinical Trial
Sign up to get notified when there's something new on the ABP 798 vs. Rituximab in RA Clinical Trial page.

Latest updates to the ABP 798 vs. Rituximab in RA Clinical Trial page
- Check5 days agoChange DetectedRevision tag updated from v3.4.2 to v3.4.3 to reflect a new page version. No study details were changed.SummaryDifference0.0%

- Check12 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedRevision: v3.4.2 is now shown as the site version, and the previous government funding lapse notice has been removed (v3.4.1). These are minor housekeeping changes and do not modify the study details or user-visible trial information.SummaryDifference0.3%

- Check41 days agoChange DetectedA government funding lapse notice is now displayed, indicating the NIH site information may not be up to date and transactions may be delayed. The page revision version has been updated to v3.4.1, replacing v3.4.0.SummaryDifference0.3%

- Check48 days agoChange DetectedA glossary toggle was added and page metadata labels were updated (Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0). No core study information changed; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check62 days agoChange DetectedRevision: v3.3.4 was added and Revision: v3.3.3 was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check84 days agoChange DetectedThe Locations section was updated with many new sites across the US and internationally (examples include Alabama, California, Sofia, Harjuma, Hesse, Saxony-Anhalt). Several previously listed locations were removed.SummaryDifference2%

Stay in the know with updates to ABP 798 vs. Rituximab in RA Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ABP 798 vs. Rituximab in RA Clinical Trial page.